Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business acquisition

Apollo in talks for J&J orthopedics unit

Analysis based on 6 articles · First reported Sep 11, 2026 · Last updated Sep 14, 2026

Sentiment
10
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The reported talks signal continued private equity appetite for large healthcare assets, which could support valuations across medical-device and healthcare services peers. For J&J, a sale or spinoff near $20 billion would sharpen its focus on higher-growth segments, while for Apollo it would be its largest healthcare deal to date, adding a large recurring-demand device business.

healthcare private equity medical devices

Apollo Global Management is reportedly in talks to acquire Johnson & Johnson's orthopedics unit, Johnson & Johnson — DePuy Synthes, in a deal that could value the business at close to $20 billion, according to Bloomberg News. The discussions are non-binding and an agreement could be reached within several weeks, though sources caution the talks could end without a deal or another bidder could emerge. Several private equity firms have reportedly shown interest in the unit. Johnson & Johnson has also retained the option of spinning off Johnson & Johnson — DePuy Synthes as a publicly traded company, a path it announced in 2025 with a target of completing a separation by mid-2027. Johnson & Johnson — DePuy Synthes makes hip, knee and shoulder implants and surgical instruments, generated $9.3 billion in sales in 2025, and would become the world's largest standalone orthopedics company if separated. The unit was created through J&J's roughly $21 billion takeover of Johnson & Johnson — DePuy Synthes in 2012, combined with its earlier DePuy business acquired from Roche. The potential deal reflects growing private equity interest in healthcare, following American Industrial Partners' $1.27 billion acquisition of Avanos Medical and the agreement by Blackstone and TPG to acquire Hologic for over $18 billion. Bloomberg L.P. — Bloomberg L.P. has estimated Johnson & Johnson — DePuy Synthes could be worth about $28 billion including debt, above the valuation currently discussed. J&J shares were little changed at $265.58, while Apollo gained 0.8% to $128.98.

stock
Apollo is reportedly in talks to acquire Johnson & Johnson — DePuy Synthes for close to $20 billion, which would be its largest healthcare deal to date and expand its asset management portfolio into medical devices.
Importance 95.0 Sentiment 15.0
stock
J&J is weighing a sale of its Johnson & Johnson — DePuy Synthes orthopedics unit to Apollo or a spinoff, part of its effort to focus on higher-growth healthcare segments; the unit generated $9.3 billion in 2025 sales.
Importance 95.0 Sentiment 10.0
subs
Johnson & Johnson — DePuy Synthes is the orthopedics unit at the center of the reported $20 billion deal talks and would become the world's largest standalone orthopedics company if separated from J&J.
Importance 90.0 Sentiment 5.0
priv
Bloomberg News first reported the Apollo-J&J talks, citing sources, making it the origin of the market-moving story.
Importance 20.0 Sentiment 0.0
per
J&J's CFO has said the company is evaluating separation options for Johnson & Johnson — DePuy Synthes, including a tax-free spinoff, and remains open to other paths.
Importance 15.0 Sentiment 0.0
priv
Cited as an example of recent private equity interest in healthcare following its $1.27 billion acquisition of Avanos Medical in April.
Importance 10.0 Sentiment 0.0
stock
Cited as part of the trend of private equity healthcare deals through its agreement with TPG to acquire Hologic.
Importance 10.0 Sentiment 0.0
stock
Cited as part of the trend of private equity healthcare deals through its agreement with Blackstone to acquire Hologic.
Importance 10.0 Sentiment 0.0
per
GlobalData's medical devices research director commented that a $20 billion deal would be a low-end valuation for Johnson & Johnson — DePuy Synthes.
Importance 10.0 Sentiment 0.0
stock
GlobalData analysts noted the spinoff would reshape J&J's operations and the joint replacement, spine hardware and trauma device markets.
Importance 10.0 Sentiment 0.0
subs
Bloomberg L.P. — Bloomberg L.P. estimated Johnson & Johnson — DePuy Synthes could be worth about $28 billion including debt, above the valuation currently being discussed.
Importance 10.0 Sentiment 0.0
stock
Mentioned as a recent private equity healthcare acquisition target, illustrating the broader deal trend.
Importance 5.0 Sentiment 0.0
stock
Mentioned as the target of a Blackstone and TPG acquisition worth over $18 billion, illustrating private equity interest in healthcare.
Importance 5.0 Sentiment 0.0
stock
Roche sold DePuy to J&J in 1998 for $3.5 billion, part of the history of the orthopedics unit now being discussed.
Importance 5.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.